Practice and challenge of precision medicine for pancreatic cancer
10.3760/cma.j.issn.0529-5815.2020.01.009
- VernacularTitle: 胰腺癌精准医疗的实践与挑战
- Author:
Xiaohan SHI
1
;
Gang JIN
Author Information
1. Department of Hepatobiliary Pancreatic Surgery, Changhai Hospital, Navy Military Medical University, Shanghai 200433, China
- Publication Type:Journal Article
- Keywords:
Pancreatic neoplasms;
Clinical protocols;
Precision medicine
- From:
Chinese Journal of Surgery
2020;58(1):37-41
- CountryChina
- Language:Chinese
-
Abstract:
Pancreatic cancer is the most lethal malignancy with an overall 5-year survival rate less than 9%, mainly due to late diagnosis and lack of effective therapeutic options.In the last decade, post-operative survival has been enhanced with advent of neoadjuvant therapy and combined adjuvant therapy.Furthermore, the information gained from the omics data, including next generation sequencing data, hasn′t yet begun to affect treatment of pancreatic cancer patients.However, in terms of precision medicine, pancreatic cancer has always lagged behind other tumors.Therefore, combined with practical experience, summary of the latest development and research progress of precise medical treatment of pancreatic cancer, especially from the fields of molecular biology and experimental models, is of critical importance. Further development of precise medicine for pancreatic cancer based on platforms using PDX and organoid model would promisingly help in effective improvement of clinical treatment.
